XNASGLTO
Market cap6mUSD
Dec 27, Last price
5.15USD
1D
-4.98%
1Q
-56.02%
IPO
-65.67%
Name
Galecto Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-31.76%
Rev. gr., 5y
%
Revenues
0k
Net income
-38m
L-38.19%
CFO
-37m
L-14.02%
Earnings
Mar 06, 2025
Profile
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 37,287 | 61,697 | 52,668 | |||
Unusual Expense (Income) | ||||||
NOPBT | (37,287) | (61,697) | (52,668) | |||
NOPBT Margin | ||||||
Operating Taxes | 417 | (475) | ||||
Tax Rate | ||||||
NOPAT | (37,287) | (62,114) | (52,193) | |||
Net income | (38,349) -38.19% | (62,041) 20.99% | (51,277) 42.29% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 2,876 | 507 | ||||
BB yield | -375.82% | -1.74% | ||||
| Debt | ||||||
Debt current | 183 | 476 | 399 | |||
Long-term debt | 132 | 1,132 | 1,295 | |||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (32,836) | (64,448) | (107,545) | |||
| Cash flow | ||||||
Cash from operating activities | (36,911) | (42,932) | (52,308) | |||
CAPEX | (196) | (223) | ||||
Cash from investing activities | 22,330 | 12,384 | (48,048) | |||
Cash from financing activities | 2,876 | 507 | ||||
FCF | (36,445) | (56,478) | (57,590) | |||
| Balance | ||||||
Cash | 33,151 | 60,224 | 100,191 | |||
Long term investments | 5,832 | 9,048 | ||||
Excess cash | 33,151 | 66,056 | 109,239 | |||
Stockholders' equity | (255,705) | (217,980) | (156,432) | |||
Invested Capital | 288,285 | 280,537 | 274,502 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 1,063 | 25,409 | 25,262 | |||
Price | 0.72 -37.39% | 1.15 -62.05% | 3.03 -75.78% | |||
Market cap | 765 -97.38% | 29,220 -61.82% | 76,543 -75.78% | |||
EV | (32,071) | (35,228) | (31,002) | |||
EBITDA | (36,457) | (61,207) | (52,227) | |||
EV/EBITDA | 0.88 | 0.58 | 0.59 | |||
Interest | 417 | |||||
Interest/NOPBT | ||||||